New combo therapy shows promise for tough bile duct cancer

NCT ID NCT07569679

Recruiting now Disease control Sponsor: Air Force Military Medical University, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to treat bile duct cancer that cannot be removed by surgery. It combines chemotherapy given directly into the liver with standard IV chemo, plus two additional drugs (adebrelimab and apatinib) that boost the immune system and block tumor growth. The trial will enroll 124 people and compare this combination to the same chemo regimen without the extra drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adebrelimab and apatinib
What this could lead to: If successful, this could lead to a new treatment option that combines chemotherapy with immunotherapy and targeted therapy to better control biliary tract cancer.
What could go wrong: This is an early Phase 2 study with only 124 participants, so results may not apply to everyone. Adding more drugs also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Locations

Air Force Military Medical University
RECRUITING

Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.